Leading global pharmaceutical company Lupin Limited (Lupin) has announced the introduction of Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, following approval from the United States Food and Drug Administration (U.S. FDA).
This generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC, is designed to inhibit premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
With estimated annual sales of USD 87 million in the U.S. as of IQVIA MAT December 2023, Ganirelix Acetate Injection is poised to address a critical medical need in the market.
About Lupin: Lupin is an innovation-driven multinational pharmaceutical company headquartered in Mumbai, India. The company’s extensive portfolio encompasses branded and generic formulations, biotechnology products, and APIs, catering to over 100 markets worldwide, including the U.S., India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.
Lupin holds a leadership position in key therapeutic segments such as cardiovascular, anti-diabetic, and respiratory, and maintains a significant presence in areas like anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health. Renowned as the third-largest pharmaceutical company in the U.S. by prescriptions, Lupin’s commitment to innovation is evident through its substantial investment of 7.9% of its revenue in research and development during FY23.
With 15 manufacturing sites, 7 research centers, and a workforce of over 20,000 professionals worldwide, Lupin has consistently earned recognition as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
For further details, please visit www.lupin.com.
